Drug labeling should be kept current

Clinical Pharmacology and Therapeutics

Volumn 73, Issue 1, 2003, Pages 4-6

  Rajpal, Anil ^b   Reidenberg, Marcus M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; AMLODIPINE; AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENZTHIAZIDE; BETAXOLOL; BISOPROLOL; BISOPROLOL FUMARATE; CALAN SR; CALCIUM ANTAGONIST; CAPTOPRIL; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENALAPRIL MALEATE; ETACRYNIC ACID; FELODIPINE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN POTASSIUM; METOPROLOL; NIFEDIPINE; PENBUTOLOL; PROPRANOLOL; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; TORASEMIDE; TRIAMTERENE; VERAPAMIL;

DRUG APPROVAL; DRUG INDICATION; DRUG INFORMATION; DRUG LABELING; DRUG PACKAGING; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HYPERTENSION; NOTE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RESPONSIBILITY;

DRUG LABELING; HUMANS; PHARMACISTS; THERAPEUTIC EQUIVALENCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0037258587     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2003.20     Document Type: Note

References (2)

1. Cohen JS. Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians' Desk Reference. Arch Intern Med 2001;161:880-5.
2. Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.